ALNYNMSHealthcare·Biotechnology#4 in industry

Alnylam Pharmaceuticals, Inc.

Reports in 3d· 2026-04-30

-13.5% · 90d

$306.93

+1.39 (+0.45%)

News

(2)

April 2026

Apr 6, 20263 weeks agoARSHealthcare

ALNYLAM PHARMACEUTICALS, INC. — ARS Filing

ALNYALNYLAM PHARMACEUTICALS, INC.

# 🧾 What This Document Is This is Alnylam's **Annual Report to Shareholders (ARS)**. Think of it as the company's yearly "report card" sent directly to its owners. It's meant to provide a comprehensive, yet digestible, overview of everything that happened in the past year—financial performance, str

Read summaryView on SEC EDGAR

Apr 6, 20263 weeks agoDEF 14AHealthcare

ALNYLAM PHARMACEUTICALS, INC. — DEF 14A Filing

ALNYALNYLAM PHARMACEUTICALS, INC.

# 🧾 What This Document Is This is Alnylam's **DEF 14A, or Definitive Proxy Statement**. It's a formal document sent to shareholders ahead of the company's annual meeting. Its purpose is to provide all the information needed for shareholders to vote on important company matters. Think of it as an ag

Read summaryView on SEC EDGAR

Key Data

Market Cap$40.95B

Open$303.87

Prev Close$305.54

Day Range$303.87 – $314.65

52W Range$245.96 – $495.55

Volume483,679

P/E (TTM)132.19

EPS$2.32

Dividend Yield—

Beta0.38

Profit Margin8.45%

Revenue Growth84.90%

Price Target$449.00(+46.3%)

Next Earnings2026-04-30(3d)

Analyst Ratings

Strong Buy28 analysts

Buy 20Hold 8Sell 0

About

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Healthcare · Biotechnology

2,500 employees

www.alnylam.com